Anti-TNF-α Antibody and Cancer Cachexia

  • Mark de Witte
  • Mark Anderson
  • Don Robinson


Cachexia is characterised by accelerated loss of adipose tissue and skeletal muscle in the context of a chronic inflammatory response [1] [3]. It is a common complication of advanced cancer [4]. About half of all cancer patients suffer from this syndrome, which is among the most debilitating and life-threatening complications [5]. The key feature of this syndrome is weight loss, but other symptoms, such as anorexia, fatigue, vomiting and anaemia, and accelerated malnutrition with depletion of whole-body lipid and protein stores are frequently observed. Cancer cachexia contributes to immobility, a propensity to infection, shortened duration of survival, and overall decreased quality of life [6].


Lean Body Mass Cancer Cachexia Hairy Cell Leukaemia Isolate Limb Perfusion Hairy Cell Leukaemia Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Tisdale MJ (2000) Biomedicine. Protein loss in cancer cachexia. Science 289:2293–2294PubMedCrossRefGoogle Scholar
  2. 2.
    Kotler DP (2000) Cachexia. Ann Intern Med 133:622–634PubMedGoogle Scholar
  3. 3.
    Ross JA, Fearon KC (2002) Eicosanoid-dependent cancer cachexia and wasting. Curr Opin Clin Nutr Metab Care 5:241–248PubMedCrossRefGoogle Scholar
  4. 4.
    Fearon KC, Moses AG (2002) Cancer cachexia. Int J Cardiol 85:73–81PubMedCrossRefGoogle Scholar
  5. 5.
    Inui A (2002) Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J Clin 52:72–91PubMedCrossRefGoogle Scholar
  6. 6.
    Wigmore SJ, Ross JA, Falconer JS et al (1996) The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition 12:S27–S30PubMedGoogle Scholar
  7. 7.
    Pirisi A (2000) US researchers find key link in muscle-wasting syndrome. Lancet 356:1249PubMedCrossRefGoogle Scholar
  8. 8.
    McGeer AJ, Detsky AS, O’Rourke K (1990) Parenteral nutrition in cancer patients undergoing chemotherapy: a meta-analysis. Nutrition 6:233–240PubMedGoogle Scholar
  9. 9.
    Balkwill F (2002) Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 13:135–141PubMedCrossRefGoogle Scholar
  10. 10.
    Szlosarek PW, Balkwill FR (2003) Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol 4:565–573PubMedCrossRefGoogle Scholar
  11. 11.
    Anonymous (2004) Fact or fiction: biochemistry to the rescue. Lancet Oncol 5:197CrossRefGoogle Scholar
  12. 12.
    Mann M (1999) Approved pharmacologic interventions for wasting: an overview and lessons learned. J Nutr 129:303S–305SPubMedGoogle Scholar
  13. 13.
    MacDonald N, Easson AM, Mazurak VC et al (2003) Understanding and managing cancer cachexia. J Am Coll Surg 197:143–161PubMedCrossRefGoogle Scholar
  14. 14.
    Falconer JS, Fearon KC, Ross JA et al (1995) Acutephase protein response and survival duration of patients with pancreatic cancer. Cancer 75:2077–2082PubMedCrossRefGoogle Scholar
  15. 15.
    Wigmore SJ, Plester CE, Richardson RA et al (1997) Changes in nutritional status associated with unresectable pancreatic cancer. Br J Cancer 75:106–109PubMedGoogle Scholar
  16. 16.
    Andreyev HJ, Norman AR, Oates J et al (1998) Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer 34:503–509PubMedCrossRefGoogle Scholar
  17. 17.
    Kern S, Hruban R, Hollingsworth MA et al (2001) A white paper: the product of a pancreas cancer think tank. Cancer Res 61:4923–4932PubMedGoogle Scholar
  18. 18.
    Tamura S, Ouchi KF, Mori K et al (1995) Involvement of human interleukin 6 in experimental cachexia induced by a human uterine cervical carcinoma xenograft. Clin Cancer Res 1:1353–1358PubMedGoogle Scholar
  19. 19.
    Oliff A, Defeo-Jones D, Boyer M et al (1987) Tumors secreting human TNF/cachectin induce cachexia in mice. Cell 50:555–563PubMedCrossRefGoogle Scholar
  20. 20.
    Sharma R, Anker SD (2002) Cytokines, apoptosis and cachexia:the potential for TNF antagonism. Int J Cardiol 85:161–171PubMedCrossRefGoogle Scholar
  21. 21.
    Argiles JM, Moore-Carrasco R, Busquets S et al (2003) Catabolic mediators as targets for cancer cachexia. Drug Discov Today 8:838–844PubMedCrossRefGoogle Scholar
  22. 22.
    Rouzer CA, Cerami A (1980) Hypertriglyceridemia associated with Trypanosoma brucei brucei infection in rabbits: role of defective triglyceride removal. Mol Biochem Parasitai 2:31–38CrossRefGoogle Scholar
  23. 23.
    Beutler B, Greenwald D, Hulmes JD et al (1985) Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature 316:552–554PubMedCrossRefGoogle Scholar
  24. 24.
    Tracey KJ, Wei H, Manogue KR et al (1988) Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med 167:1211–1227PubMedCrossRefGoogle Scholar
  25. 25.
    Darling G, Fraker DL, Jensen JC et al (1990) Cachectic effects of recombinant human tumor necrosis factor in rats. Cancer Res 50:4008–4013PubMedGoogle Scholar
  26. 26.
    Llovera M, Lopez-Soriano FJ, Argiles JM (1993) Effects of tumor necrosis factor-alpha on muscle-protein turnover in female Wistar rats. J Natl Cancer Inst 85:1334–1339PubMedCrossRefGoogle Scholar
  27. 27.
    Llovera M, Garcia-Martinez C, Lopez-Soriano J et al (1998) Protein turnover in skeletal muscle of tumour-bearing transgenic mice overexpressing the soluble TNF receptor-1. Cancer Lett 130:19–27PubMedCrossRefGoogle Scholar
  28. 28.
    Guttridge DC, Mayo MW, Madrid LV et al (2000) NFkappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 289:2363–2366PubMedCrossRefGoogle Scholar
  29. 29.
    Megeney LA, Kablar B, Garrett K et al (1996) MyoD is required for myogenic stem cell function in adult skeletal muscle. Genes Dev 10:1173–1183PubMedCrossRefGoogle Scholar
  30. 30.
    Argiles JM, Lopez-Soriano J, Busquets S et al (1997) Journey from cachexia to obesity by TNF. FASEB J 11:743–751PubMedGoogle Scholar
  31. 31.
    Bossola M, Muscaritoli M, Bellantone R et al (2000) Serum tumour necrosis factor-alpha levels in cancer patients are discontinuous and correlate with weight loss. Eur J Clin Invest 30:1107–1112PubMedCrossRefGoogle Scholar
  32. 32.
    Mantovani G, Macciò A, Mura L et al (2000) Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J Mol Med 78:554–561PubMedCrossRefGoogle Scholar
  33. 33.
    Nakashima J, Tachibana M, Ueno M et al (1998) Association between tumor necrosis factor in serum and cachexia in patients with prostate cancer. Clin Cancer Res 4:1743–1748PubMedGoogle Scholar
  34. 34.
    Falconer JS, Fearon KC, Plester CE et al (1994) Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg 219:325–331PubMedCrossRefGoogle Scholar
  35. 35.
    Karayiannakis AJ, Syrigos KN, Polychronidis A et al (2001) Serum levels of tumor necrosis factor-alpha and nutritional status in pancreatic cancer patients. Anticancer Res 21:1355–1358PubMedGoogle Scholar
  36. 36.
    Sherry BA, Gelin J, Fong Y et al (1989) Anticachectin/tumor necrosis factor-alpha antibodies attenuate development of cachexia in tumor models. FASEBJ 3:1956–1962Google Scholar
  37. 37.
    Trikha M (2002) Combined blockade of human and mouse TNF inhibits cancer cachexia in nude mice. Centocor Technical Report Biorestr 315 (Internal Centocor Report), Centocor Inc, MalvernGoogle Scholar
  38. 38.
    Siegel SA, Shealy DJ, Nakada MT et al (1995) The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine 7:15–25PubMedCrossRefGoogle Scholar
  39. 39.
    Torelli GF, Meguid MM, Moldawer LL et al (1999) Use of recombinant human soluble TNF receptor in anorectic tumor-bearing rats. Am J Physiol 277:R850–R855PubMedGoogle Scholar
  40. 40.
    Truyens C, Torrico F, Angelo-Barrios A et al (1995) The cachexia associated with Trypanosoma cruzi acute infection in mice is attenuated by anti-TNF-alpha,but not by anti-IL-6 or anti-IFN-gamma antibodies. Parasite Immunol 17:561–568PubMedGoogle Scholar
  41. 41.
    Haslett PA (1998) Anticytokine approaches to the treatment of anorexia and cachexia. Semin Oncol 25:53–57PubMedGoogle Scholar
  42. 42.
    Steensma DP, Mesa RA, Li CY et al (2002) Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study. Blood 99:2252–2254PubMedCrossRefGoogle Scholar
  43. 43.
    Fonseca J, Canhao H, Resende C et al (2002) Weight gain associated with the administration of tumor necrosis factor alpha antagonists in patients with rheumatoid arthritis. EULAR (Annual European Congress of Rheumatology). Arthritis Reum 46:S170 (abs)Google Scholar
  44. 44.
    Eggermont AM, de Wilt JH, ten Hagen TL (2003) Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 4:429–437PubMedCrossRefGoogle Scholar
  45. 45.
    Eggermont AM, ten Hagen TL (2003) Tumor necrosis factor-based isolated limb perfusion for soft tissue sarcoma and melanoma: ten years of successful antivascular therapy. Curr Oncol Rep 5:79–80PubMedCrossRefGoogle Scholar
  46. 46.
    Arnott CH, Scott KA, Moore RJ et al (2004) Expression of both TNF-alpha receptor subtypes is essential for optimal skin tumour development. Oncogene 23:1902–1910PubMedCrossRefGoogle Scholar
  47. 47.
    Malik ST, Griffin DB, Fiers W et al (1989) Paradoxical effects of tumour necrosis factor in experimental ovarian cancer. Int J Cancer 44:918–925PubMedCrossRefGoogle Scholar
  48. 48.
    Scott KA, Moore RJ, Arnott CH et al (2003) An anti-tumor necrosis factor-alpha antibody inhibits the development of experimental skin tumors. Mol Cancer Ther 2:445–451PubMedGoogle Scholar
  49. 49.
    Montserrat E (1997) Chronic lymphoproliferative disorders. Curr Opin Oncol 9:34–41PubMedGoogle Scholar
  50. 50.
    Holden RJ, Pakula IS, Mooney PA (1998) An immunological model connecting the pathogenesis of stress, depression and carcinoma. Med Hypotheses 51:309–314PubMedCrossRefGoogle Scholar
  51. 51.
    Tselepis C, Perry I, Dawson C et al (2002) Tumour necrosis factor-alpha in Barrett’s oesophagus: a potential novel mechanism of action. Oncogene 21:6071–6081PubMedCrossRefGoogle Scholar
  52. 52.
    Barak V, Nisman B, Polliack A (1999) The tumor necrosis factor family and correlation with disease activity and response to treatment in hairy cell leukemia. Eur J Haematol 62:71–75PubMedCrossRefGoogle Scholar
  53. 53.
    Schiller JH, Bittner G, Spriggs DR (1992) Tumor necrosis factor,but not other hematopoietic growth factors, prolongs the survival of hairy cell leukemia cells. Leuk Res 16:337–346PubMedCrossRefGoogle Scholar
  54. 54.
    Hideshima T, Chauhan D, Schlossman R et al (2001) The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 20:4519–4527PubMedCrossRefGoogle Scholar
  55. 55.
    Foa R, Massaia M, Cardona S et al (1990) Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: a possible regulatory role of TNF in the progression of the disease. Blood 76:393–400PubMedGoogle Scholar
  56. 56.
    Huang D, Reittie JE, Stephens S et al (1992) Effects of anti-TNF monoclonal antibody infusion in patients with hairy cell leukaemia. Br J Haematol 81:231–234PubMedGoogle Scholar
  57. 57.
    Friess H, Guo XZ, Nan BC et al (1999) Growth factors and cytokines in pancreatic carcinogenesis. Ann NY Acad Sci 880:110–121PubMedCrossRefGoogle Scholar
  58. 58.
    Cope AP, Londei M, Chu NR et al (1994) Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 94:749–760PubMedCrossRefGoogle Scholar
  59. 59.
    D’Haens G, Ceuppens J, Colpaert S et al (1997) Restoration of decreased in vitro lymphocyte proliferative response to mycobacteria and mitogens after single infusion of chimeric anti-TNF alpha antibodies in Crohn’s disease. Gastroenterology 112:A595 (abs)CrossRefGoogle Scholar
  60. 60.
    Meenan J, Hommes D, van Dullemen H (1997) The influence of TNF alpha mAb, cA2, on circulating lymphocyte populations. Gastroenterology 112:A1039 (abs)CrossRefGoogle Scholar
  61. 61.
    Knight DM, Trinh H, Le J et al (1993) Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 30:1443–1453PubMedCrossRefGoogle Scholar
  62. 62.
    Nahar IK, Shojania K, Marra CA et al (2003) Infliximab treatment of rheumatoid arthritis and Crohn’s disease. Ann Pharmacother 37:1256–1265PubMedCrossRefGoogle Scholar
  63. 63.
    Hommes DW, van Deventer SJ (2003) Infliximab therapy in Crohn’s disease:safety issues. Neth J Med 61:100–104PubMedGoogle Scholar
  64. 64.
    Mikuls TR, Moreland LW (2003) Benefit-risk assessment of infliximab in the treatment of rheumatoid arthritis. Drug Saf 26:23–32PubMedCrossRefGoogle Scholar
  65. 65.
    Khanna D, McMahon M, Furst DE (2004) Safety of tumour necrosis factor-alpha antagonists. Drug Saf 27:307–324PubMedCrossRefGoogle Scholar
  66. 66.
    Anonymous (2003) REMICADE® (infliximab) package insert. Centocor Inc, MalvernGoogle Scholar
  67. 67.
    Marty FM, Lee SJ, Fahey MM et al (2003) Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 102:2768–2776PubMedCrossRefGoogle Scholar
  68. 68.
    Smith KJ, Skelton HG (2001) Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgGl-Fc fusion complex therapy. J Am Acad Dermatol 45:953–956PubMedCrossRefGoogle Scholar
  69. 69.
    Kavanaugh A, Keystone EC (2003) The safety of biologic agents in early rheumatoid arthritis. Clin Exp Rheumatol 21:S203–S208 (abs)PubMedGoogle Scholar
  70. 70.
    Wolfe F, Michaud K (2003) Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-TNF therapy in 18,572 patients. Arthritis Rheum 48:S242 (abs)Google Scholar
  71. 71.
    Lee JH, Slifman NR, Gershon SK et al (2002) Lifethreatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 46:2565–2570PubMedCrossRefGoogle Scholar
  72. 72.
    Brown SL, Greene MH, Gershon SK et al (2002) Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 46:3151–3158PubMedCrossRefGoogle Scholar
  73. 73.
    Slifman NR, Gershon SK, Lee JH et al (2003) Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 48:319–324PubMedCrossRefGoogle Scholar
  74. 74.
    Colombel JF, Loftus EVJr, Tremaine WJ et al (2004) The safety profile of infliximab in patients with Crohn’s disease: the Mayo clinic experience in 500 patients. Gastroenterology 126:19–31PubMedCrossRefGoogle Scholar
  75. 75.
    Ramesh G, Reeves WB (2002) TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 110:835–842PubMedCrossRefGoogle Scholar
  76. 76.
    Delanian S, Porcher R, Balla-Mekias S et al (2003) Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis. J Clin Oncol 21:2545–2550PubMedCrossRefGoogle Scholar
  77. 77.
    Rube CE, van Valen F, Wilfert F et al (2003) Ewing’s sarcoma and peripheral primitive neuroectodermal tumor cells produce large quantities of bioactive tumor necrosis factor-alpha (TNF-alpha) after radiation exposure. Int J Radiat Oncol Biol Phys 56:1414–1425PubMedCrossRefGoogle Scholar
  78. 78.
    Azuma Y, Kaji K, Katogi R et al (2000) Tumor necrosis factor-alpha induces differentiation of and bone résorption by osteoclasts. J Biol Chem 275:4858–4864PubMedCrossRefGoogle Scholar
  79. 79.
    Schafers M, Lee DH, Brors D et al (2003) Increased sensitivity of injured and adjacent uninjured rat primary sensory neurons to exogenous tumor necrosis factoralpha after spinal nerve ligation. J Neurosci 23:3028–3038PubMedGoogle Scholar
  80. 80.
    Tobinick EL (2003) Targeted etanercept for treatment-refractory pain due to bone metastasis: two case reports. Clin Ther 25:2279–2288PubMedCrossRefGoogle Scholar
  81. 81.
    Anonymous (2002) American Thoracic Society statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166:111–117Google Scholar
  82. 82.
    Cella D, Eton DT, Lai JS et al (2002) Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 24:547–561PubMedCrossRefGoogle Scholar
  83. 83.
    Johnson JR, Williams G, Pazdur R (2003) End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 21:1404–1411PubMedCrossRefGoogle Scholar
  84. 84.
    Steer CB, Marx GM, Harper PG (2001) Is there quality in clinical benefit? Ann Oncol 12:1191–1193PubMedCrossRefGoogle Scholar
  85. 85.
    Patrick-Miller LJ (2003) Is there a role for the assessment of health-related quality of life in the clinical evaluation of novel cytostatic agents? Clin Cancer Res 9:2040–2048 Commentary re: LoRusso PM (2003) Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin Cancer Res 9:1990-1994Google Scholar
  86. 86.
    Cleeland CS, Bennett GJ, Dantzer R et al (2003) Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokineimmunologic model of cancer symptoms. Cancer 97:2919–2925PubMedCrossRefGoogle Scholar
  87. 87.
    Pfitzenmaier J, Vessella R, Higano CS et al (2003) Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer 97:1211–1216PubMedCrossRefGoogle Scholar
  88. 88.
    Raison CL, Miller AH (2003) Depression in cancer: new developments regarding diagnosis and treatment. Biol Psychiatry 54:283–294PubMedCrossRefGoogle Scholar
  89. 89.
    Chassany O, Sagnier P, Marquis P et al (2002) Patient reported outcomes: the example of health-related quality of life. A European guidance document for the improved integration of health-related quality of life assessments in the drug regulatory process. Drug Inf J 36:209–238Google Scholar
  90. 90.
    Hirschfeld S, Pazdur R (2002) Oncology drug development: United States Food and Drug Administration perspective. Crit Rev Oncol Hematol 42:137–143PubMedCrossRefGoogle Scholar
  91. 91.
    Revicki DA, Osoba D, Fairclough D et al (2000) Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res 9:887–900PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2006

Authors and Affiliations

  • Mark de Witte
    • 1
  • Mark Anderson
    • 1
  • Don Robinson
    • 1
  1. 1.Clinical Hematology/Oncology, CentocorMalvernUSA

Personalised recommendations